Cadila Healthcare Ltd is a specialty and generic drug manufacturing company. Cadila is present in the generics segment of pharmaceutical markets across the globe. In some countries, the company is mandated by law to reduce the prices of the products as the governments of these countries resort to periodic price reductions to keep the healthcare costs down. The vast majority of the company's revenue is generated in India, followed by the United States. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.